These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 16177827

  • 1. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL, Morgentaler A.
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [Abstract] [Full Text] [Related]

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

  • 3. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.
    Int J Impot Res; 2008 May; 20(6):561-5. PubMed ID: 18843272
    [Abstract] [Full Text] [Related]

  • 4. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF.
    Cancer; 2007 Feb 01; 109(3):536-41. PubMed ID: 17183557
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A, Rhoden EL.
    Urology; 2006 Dec 01; 68(6):1263-7. PubMed ID: 17169647
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL, Morgentaler A.
    J Urol; 2003 Dec 01; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI.
    Int J Impot Res; 2008 Dec 01; 20(2):213-7. PubMed ID: 17898800
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M.
    Int J Impot Res; 2013 Jan 01; 25(1):24-8. PubMed ID: 22971614
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
    McLaren D, Siemens DR, Izard J, Black A, Morales A.
    BJU Int; 2008 Nov 01; 102(9):1142-6. PubMed ID: 18540933
    [Abstract] [Full Text] [Related]

  • 16. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G.
    Postgrad Med; 2013 Mar 01; 125(2):30-9. PubMed ID: 23816769
    [Abstract] [Full Text] [Related]

  • 17. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May 01; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 18. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007 May 01; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy and the risk of prostate cancer. Is there a link?
    Barqawi A, Crawford ED.
    Int J Impot Res; 2006 May 01; 18(4):323-8. PubMed ID: 16281043
    [Abstract] [Full Text] [Related]

  • 20. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 01; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.